drugset / Trial / NCT06430385
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
RandomizedSequentialQuadruple-blindTreatment
Summary
The primary purpose of this study is to evaluate the safety and tolerability of ION440.
Timeline
- Start
- 2024-10-21
- Primary completion
- 2027-09
- Completion
- 2030-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ION440 | Unknown | — | Intrathecal |